Safety and long-term efficacy of hybrid-argon plasma coagulation for the treatment of Barrett’s esophagus: An Australian pilot study (with video)
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Five to ten percent of all patients undergoing radiofrequency ablation (RFA), which is the most established technique for Barrett’s esophagus (BE) ablation-develop strictures. Hybrid-argon plasma coagulation (APC) combines APC with submucosal saline injection that was recently developed to tackle this problem. The aims of this pilot study were to evaluate the feasibility, tolerance, safety and long-term efficacy of hybrid-APC for the treatment of BE. Methods: Patients with histological proven BE were selected for hybrid-APC. Prior to APC thermal ablation the mucosa was lifted using a submucosal high-pressure water jet injection system (Erbejet 2; Erbe, Tuebingen, Germany). Short-term (< 48 hours) and long-term (> 48 hours) safety were evaluated. Efficacy of ablation was measured at 3, 6, 12 and 24 months at follow-up endoscopy by evidence of macroscopically complete resolution of BE mucosa and/or histologically complete resolution of intestinal metaplasia (CRIM). Results: Eleven patients were included in the study (average age, 68.2 years; male 72.7%). Eight patients (72.7%) were treatment naive, 9.1% (n = 1) had prior RFA and 18.2% (n = 2) had prior endoscopic mucosal resection. Two patients were excluded from the study. Nine patients (100%) had macroscopic remission and 88.9% (n = 8) had macroscopic remission and microscopic CRIM at 24 months after hybrid-APC ablation. No treatment-related stricture or other major complications were observed, 1 patient (11.1%) reported minor adverse effects. Conclusion: In this prospective pilot study, hybrid-APC appears safe, feasible and effective after 24 months, which has not been evaluated so far. Further large, multi-centre trials are warranted to confirm the present results.
Abstract
Background: Five to ten percent of all patients undergoing radiofrequency ablation (RFA), which is the most established technique for Barrett’s esophagus (BE) ablation-develop strictures. Hybrid-argon plasma coagulation (APC) combines APC with submucosal saline injection that was recently developed to tackle this problem. The aims of this pilot study were to evaluate the feasibility, tolerance, safety and long-term efficacy of hybrid-APC for the treatment of BE. Methods: Patients with histological proven BE were selected for hybrid-APC. Prior to APC thermal ablation the mucosa was lifted using a submucosal high-pressure water jet injection system (Erbejet 2; Erbe, Tuebingen, Germany). Short-term (< 48 hours) and long-term (> 48 hours) safety were evaluated. Efficacy of ablation was measured at 3, 6, 12 and 24 months at follow-up endoscopy by evidence of macroscopically complete resolution of BE mucosa and/or histologically complete resolution of intestinal metaplasia (CRIM). Results: Eleven patients were included in the study (average age, 68.2 years; male 72.7%). Eight patients (72.7%) were treatment naive, 9.1% (n = 1) had prior RFA and 18.2% (n = 2) had prior endoscopic mucosal resection. Two patients were excluded from the study. Nine patients (100%) had macroscopic remission and 88.9% (n = 8) had macroscopic remission and microscopic CRIM at 24 months after hybrid-APC ablation. No treatment-related stricture or other major complications were observed, 1 patient (11.1%) reported minor adverse effects. Conclusion: In this prospective pilot study, hybrid-APC appears safe, feasible and effective after 24 months, which has not been evaluated so far. Further large, multi-centre trials are warranted to confirm the present results.
참고문헌 (27)
- Qumseya B, "ASGE guideline on screening and surveillance of Barrett’s esophagus", Gastrointest Endosc, 90, pp.335~359.e2 (2019)
- Weusten B, "Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement", Endoscopy, 49, pp.191~198 (2017)
- Bennett C, "Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process", Gastroenterology, 143, pp.336~346 (2012)
- Ell C, "Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett’s esophagus", Gastroenterology, 118, pp.670~677 (2000)
- Sharma P, "AGA clinical practice update on endoscopic treatment of Barrett’s esophagus with dysplasia and", or early cancer:expert review, 2020, pp.158, 760~769
- Schwameis K, "Workload, recurrence, quality of life and long-term efficacy of endoscopic therapy for high-grade dysplasia and intramucosal esophageal adenocarcinoma", Ann Surg, 271, pp.701~708 (2020)
- Phoa KN, "Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study", Gastroenterology, 145, pp.96~104 (2013)
- Omar M, "Anatomic location of Barrett’s esophagus recurrence after endoscopic eradication therapy:development of a simplified surveillance biopsy strategy", Gastrointest Endosc, 90, pp.395~403 (2019)
- Qumseya BJ, "Adverse events after radiofrequency ablation in patients with Barrett’s esophagus: a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 14, pp.1086~1095.e6 (2016)
- Fujii-Lau LL, "Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett’s esophagus: a systematic review and meta-analysis", Endosc Int Open, 5, pp.E430~E449 (2017)
- Deviere J, "Argon plasma coagulation therapy for ablation of Barrett’s oesophagus", Gut, 51, pp.763~764 (2002)
- Madisch A, "Long-term follow-up after complete ablation of Barrett’s esophagus with argon plasma coagulation", World J Gastroenterol, 11, pp.1182~1186 (2005)
- Barr H, "Endoscopic therapy for Barrett’s oesophagus", Gut, 54, pp.875~884 (2005)
- Milashka M, "Sixteen-year follow-up of Barrett’s esophagus, endoscopically treated with argon plasma coagulation", United European Gastroenterol J, 2, pp.367~373 (2014)
- Manner H, "Efficacy and safety of Hybrid-APC for the ablation of Barrett’s esophagus", Surg Endosc, 30, pp.1364~1370 (2016)
- Kashin SV, "Mo2016 the new hybrid argon plasma coagulation (Hybrid APC) for endoscopic ablation of Barrett’s esophagus (BE): the results of the pilot trial", Gastrointest Endosc, 83, pp.AB495~ (2016)
- Sharma P, "The development and validation of an endoscopic grading system for Barrett’s esophagus:the Prague C & M criteria", Gastroenterology, 131, pp.1392~1399 (2006)
- Desai M, "Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett’s esophagus-related neoplasia: a systematic review and pooled analysis", Gastrointest Endosc, 85, pp.482~495.e4 (2017)
- Qumseya BJ, "Disease progression in Barrett’s low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis", Am J Gastroenterol, 112, pp.849~865 (2017)
- Visrodia K, "Cryotherapy for persistent Barrett’s esophagus after radiofrequency ablation: a systematic review and meta-analysis", Gastrointest Endosc, 87, pp.1396~1404.e1 (2018)
- Manner H, "The tissue effect of argon-plasma coagulation with prior submucosal injection (Hybrid-APC)versus standard APC: a randomized ex-vivo study", United European Gastroenterol J, 2, pp.383~390 (2014)
- Manner H, "Ablation of nonneoplastic Barrett’s mucosa using argon plasma coagulation with concomitant esomeprazole therapy (APBANEX): a prospective multicenter evaluation", Am J Gastroenterol, 101, pp.1762~1769 (2006)
- Saligram S, "Longterm results of the mucosal ablation of Barrett’s esophagus: efficacy and recurrence", Endosc Int Open, 3, pp.E189~E194 (2015)
- Norton ID, "Efficacy of colonic submucosal saline solution injection for the reduction of iatrogenic thermal injury", Gastrointest Endosc, 56, pp.95~99 (2002)
- Mitsuhiro Fujishiro, "Submucosal Injection of Normal Saline can Prevent Unexpected Deep Thermal Injury of Argon Plasma Coagulation in the in vivo Porcine Stomach", Gut and Liver, 2(2), pp.95~98 (2008), 거트앤리버 소화기연관학회협의회
- Fleischer DE, "Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial", Endoscopy, 42, pp.781~789 (2010)
- Akiyama J, "Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett’s esophagus", Dig Dis Sci, 57, pp.2625~2632 (2012)